A new study from the University of Missouri is helping veterinarians and pet owners better understand how to treat thyroid cancer in dogs by studying how to improve treatment with a type of therapy called radioactive iodine. It lays the important groundwork for delivering more tailored and effective treatment options.

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on Lung Cancer (WCLC).

A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers, in a new article published in the Journal of Analytical Atomic Spectrometry,

Using nanoparticles shaped like bottlebrushes, MIT chemists can deliver a large range of chemotherapy drugs directly to tumor cells, which could reduce the side effects of treatment.

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

A new study presented today reports encouraging long-term survival outcomes from an experimental viral  immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.